3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Azacitidine
26
venetoclax
12
Peripheral Blood Stem Cell Transplantation
12
fludarabine phosphate
10
Mycophenolic Acid
9
Whole-Body Irradiation
8
Cyclosporine
8
Cytarabine
7
Cyclophosphamide
6
Filgrastim
5
Decitabine
5
Busulfan
5
Methotrexate
4
fludarabine
3
aldesleukin
3
Tacrolimus
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Cytogenetic Analysis
3
Cyclosporins
3
Biopsy
3
tipifarnib
2
tagraxofusp
2
ruxolitinib
2
quizartinib
2
eprenetapopt
2
axatilimab
2
X-Rays
2
Transplantation
2
Topotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Myelomonocytic, Chronic
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled